866-997-4948(US-Canada Toll Free)

Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018

Published By :

Current Partnering

Published Date : Nov 2018

Category :

Pharmaceutical

No. of Pages : 1000 Pages

The Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the precision medicine in oncology partnering agreements entered into by the worlds leading companies.

Comprehensive directory of precision medicine in oncology deals since 2010
Precision medicine in oncology contract documents
Precision medicine in oncology agreement terms
Precision medicine in oncology agreement structure
Top precision medicine in oncology deals by value
Most active precision medicine in oncology dealmakers

The Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the precision medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors precision medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of precision Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in precision Medicine in Oncology dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading precision Medicine in Oncology deals since 2010. Deals are listed by headline value, signed by big pharma, most active precision Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of precision Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of precision Medicine in Oncology partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of precision Medicine in Oncology partnering deals signed and announced since Jan 2010. The chapter is organized by specific precision Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by precision Medicine in Oncology partnering company A-Z, deal type definitions and precision Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in precision Medicine in Oncology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of precision Medicine in Oncology technologies and products.

Report scope

Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018 is intended to provide the reader with an in-depth understanding of the precision medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018 includes:

Trends in precision medicine in oncology dealmaking in the biopharma industry since 2010
Analysis of precision medicine in oncology deal structure
Case studies of real-life precision medicine in oncology deals
Access to over 700 precision medicine in oncology deals
The leading precision medicine in oncology deals by value since 2010
Most active precision medicine in oncology dealmakers since 2010
The leading precision medicine in oncology partnering resources

In Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific technology target
 

Each deal title links via Weblink to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Global Precision Medicine in Oncology Partnering Terms and Agreements 2010 to 2018 provides the reader with the following key benefits:

In-depth understanding of precison medicine in oncology deal trends since 2010
Analysis of the structure of precision medicine in oncology agreements with numerous real life case studies
Comprehensive access to precision medicine in oncology deals entered into by the world’s biopharma companies
Detailed access to actual precision medicine in oncology contracts entered into by leading biopharma companies
Insight into the terms included in a precision medicine in oncology agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Precision Medicine in Oncology dealmaking

2.1. Introduction
2.2. Precision Medicine in Oncology partnering over the years
2.3. Most active Precision Medicine in Oncology dealmakers
2.4. Precision Medicine in Oncology partnering by deal type
2.5. Precision Medicine in Oncology partnering by therapy area
2.6. Deal terms for Precision Medicine in Oncology partnering
2.6.1 Precision Medicine in Oncology partnering headline values
2.6.2 Precision Medicine in Oncology deal upfront payments
2.6.3 Precision Medicine in Oncology deal milestone payments 
2.6.4 Precision Medicine in Oncology royalty rates

Chapter 3 – Leading Precision Medicine in Oncology deals

3.1. Introduction
3.2. Top Precision Medicine in Oncology deals by value

Chapter 4 – Most active Precision Medicine in Oncology dealmakers

4.1. Introduction
4.2. Most active Precision Medicine in Oncology dealmakers
4.3. Most active Precision Medicine in Oncology partnering company profiles

Chapter 5 – precision Medicine in Oncology contracts dealmaking directory

5.1. Introduction
5.2. Precision Medicine in Oncology contracts dealmaking directory

Chapter 6 – Precision Medicine in Oncology dealmaking by technology type

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Precision Medicine in Oncology deals by company A-Z

Appendix 2 – Precision Medicine in Oncology deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed

Appendix 3 – Precision Medicine in Oncology deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Spin out
Sub-license
Supply 
Technology transfer

Appendix 4 – Precision Medicine in Oncology deals by therapy area

Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
Esophageal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Solid tumors
Symptoms
Oral mucositis
Testicular cancer
Thyroid cancer

Appendix 5 –Deal type definitions

About Wildwood Ventures

List of Chart

Figure 1: Precision Medicine in Oncology partnering since 2010
Figure 2: Active Precision Medicine in Oncology dealmaking activity– 2010 to 2018
Figure 3: Precision Medicine in Oncology partnering by deal type since 2010
Figure 4: Precision Medicine in Oncology partnering by disease type since 2010
Figure 5: Precision Medicine in Oncology deals with a headline value
Figure 6: Precision Medicine in Oncology deals with an upfront value
Figure 7: Precision Medicine in Oncology deals with a milestone value
Figure 8: Precision Medicine in Oncology deals with a royalty rate value
Figure 9: Top Precision Medicine in Oncology deals by value since 2010
Figure 10: Most active Precision Medicine in Oncology dealmakers 2010 to 2018
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *